文献速递肺栓塞与肺血管病

试验时长与联合治疗试验中风险降低的关系:肺动脉高压系统综述

Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review.
PubMed 文献 · Chest · 2017-11-23

该系统综述与荟萃分析纳入15项RCT共3801例肺动脉高压患者,比较联合治疗与单药治疗。临床恶化相对风险随试验时长增加而升高(R2=0.67,P=.0002),但需治疗人数(NNT)与时长无关(平均NNT=7;R2=0.02;P=.65)。长期事件驱动试验中NNT至52周逐渐下降后稳定,而RR从第16周约0.40升至第104周约0.68。

要点

  • 联合治疗临床恶化的RR与试验时长正相关,NNT与时长无关。
  • 长期事件驱动试验中NNT至52周逐渐下降,此后保持稳定。
  • 超过6至12个月后绝对风险降低相对恒定,超长联合试验必要性存疑。

核心结论

  • 在肺动脉高压联合治疗对比单药治疗的试验中,临床恶化的绝对风险降低在治疗超过6至12个月后相对恒定。
  • 上述结果对肺动脉高压联合治疗需设计超长时长试验的必要性提出质疑。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Library(1990年1月至2016年9月)的RCT。
  • 纳入15项比较肺动脉高压特异性治疗联合治疗与单药治疗的RCT,共3801例患者。
  • 主要结局为临床恶化风险,采用混合效应加权荟萃回归评估试验时长与RR及NNT的相关性。

主要发现

  • 临床恶化的RR与试验时长正相关(R2=0.67,P=.0002)。
  • NNT与试验时长无显著相关(平均NNT=7;R2=0.02;P=.65)。
  • 长期事件驱动试验中,平均NNT至52周随访逐渐下降,此后保持稳定。
  • 平均RR从第16周约0.40逐步升至第104周约0.68。

临床怎么用

  • 解读肺动脉高压联合治疗试验时需考虑试验时长对RR和NNT的影响。
  • 超过6至12个月后绝对风险降低相对恒定,可据此评估长期联合治疗试验的设计必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relative risk (RR) and number needed-to-treat (NNT) are frequently time-dependant measures. We performed a systematic review and meta-analysis to assess whether trial duration influenced the relative and absolute risk of worsening in randomized controlled trials (RCTs) comparing combination therapy (CT) of pulmonary arterial hypertension (PAH)-specific therapies vs monotherapy (MT). METHODS: We searched MEDLINE, Embase, and the Cochrane Library (January 1990 to September 2016) for RCTs assessing CT compared with MT in PAH. The primary outcome was the risk of clinical worsening. We assessed whether trial duration correlated with RR and NNT using weighted meta-regression with mixed effects. Changes in NNT overtime were also assessed using data from long-term event-driven trials. RESULTS: There were 3,801 patients throughout 15 studies included. The RR for clinical worsening positively correlated with trial duration (R2 = 0.67, P = .0002), whereas the NNT did not (mean NNT, 7; R2 = 0.02; P = .65). Among long-term event-driven trials, the mean NNT progressively decreased until 52 weeks of follow-up, being stable thereafter. Conversely, the mean RR progressively increased from approximately 0.40 at week 16 to approximately 0.68 at week 104. CONCLUSIONS: Absolute risk reduction of clinical worsening was relatively constant beyond 6 to 12 months of treatment in clinical trials comparing CT with MT in PAH. These results question the need for CT trials of very long duration in PAH.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lajoie AC, Guay CA, Lega JC, et al. Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review. Chest. 2017. PMID: 29175359. doi:10.1016/j.chest.2017.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。